Literature DB >> 2295800

Development of the autoimmune B cell repertoire in MRL-lpr/lpr mice.

D M Klinman1, R A Eisenberg, A D Steinberg.   

Abstract

The processes responsible for the production of autoantibodies have been shown to include both Ag-specific and generalized (polyclonal) forms of B cell activation. The relative contribution and temporal association of these processes to the genesis of systemic autoimmunity are incompletely understood. To study this relationship, the B cell repertoires of MRL-lpr/lpr mice were analyzed by ELISA spot assay over an 8-mo period. Between 6 and 12 wk of age, the number of splenic lymphocytes producing antibodies reactive with both autoantigens and conventional Ag increased proportionately. The repertoires of MRL-lpr/lpr mice under 12 wk were dominated by IgM-secreting B cells that showed no bias toward the production of specific autoantibodies. From 12 to 38 wk of age, an increasing proportion of animals developed repertoires dominated by IgG-secreting B cells that were skewed toward reactivity against one or very few (auto)antigens. Although there was no single Ag against which all mice developed skewed reactivity, 55% of MRL-lpr/lpr adults had increased numbers of B cells producing antibodies to the Sm Ag and 13 to 16% developed increased reactivity toward DNA, myosin, histone, thyroglobulin, or T cells. These data indicate that generalized (polyclonal) B cell activation dominates early repertoire development whereas (auto)-antigen-specific responses become increasingly important during the latter stages of disease in these autoimmune-prone mice.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295800

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Anti-Sm autoantibodies in systemic lupus erythematosus mice: a model system for disease-specific autoreactivity.

Authors:  R A Eisenberg
Journal:  Springer Semin Immunopathol       Date:  1992

2.  Qualitative difference of anti-DNA antibody-producing cell precursors in the pre-immune B cell repertoire between normal and lupus-prone mice.

Authors:  K Iwai; T Tsubata; Y Katsura; S Kumagai; H Imura
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

3.  IgM anti-myeloperoxidase antibody-secreting lymphocytes are present in the peripheral repertoire of lupus mice but rarely differentiate into IgG-producing cells.

Authors:  O Vittecoq; F Brard; F Jovelin; X Le Loet; F Tron; D Gilbert
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

4.  Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease.

Authors:  D M Klinman
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

5.  Repertoire cloning of lupus anti-DNA autoantibodies.

Authors:  P Roben; S M Barbas; L Sandoval; J M Lecerf; B D Stollar; A Solomon; G J Silverman
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

6.  Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane.

Authors:  M Satoh; A Kumar; Y S Kanwar; W H Reeves
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

Review 7.  Abnormalities in the regulation of variable region genes that encode for antibodies to DNA may be a central factor in the pathogenesis of systemic lupus erythematosus.

Authors:  A K Singh
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

Review 8.  Mechanisms of autoimmunity.

Authors:  Robert Eisenberg
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

9.  Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen.

Authors:  R W Burlingame; R L Rubin; R S Balderas; A N Theofilopoulos
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

10.  Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation.

Authors:  A Shirai; M Cosentino; S F Leitman-Klinman; D M Klinman
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.